Tick-borne encephalitis virus (TBEV) infection in pregnancy: Absence of virus transmission to the fetuses despite severe maternal disease - A case study
- PMID: 32723645
- DOI: 10.1016/j.ttbdis.2020.101491
Tick-borne encephalitis virus (TBEV) infection in pregnancy: Absence of virus transmission to the fetuses despite severe maternal disease - A case study
Abstract
Tick-borne encephalitis (TBE) is an emerging infectious disease in large parts of Europe and Asia. Whereas other members of the Flaviviridae family can harm fetal development, there are only very few reports on TBE virus (TBEV) infections during pregnancy. Thus, the implications for fetal health remain largely unknown. In this study, we present detailed pre- and postnatal health assessment of three children in the context of severe maternal TBEV infection during pregnancy. Following acute TBEV infection of the mothers, intrauterine growth and development of all children were assessed by repetitive prenatal ultrasound. Postnatal examinations included clinical and virological analyses over a follow-up period of 18 months. Prenatally, no signs of intrauterine growth restrictions were observed. All neonates were delivered at term. Umbilical cord blood of the newborns tested negative for TBEV RNA. Virus-specific IgG antibodies were positive at birth but negative at 9 and 11 months of age. Importantly, IgM antibodies remained negative throughout the period of observation. Taken together, these clinical and virological data strongly suggest that fetal TBEV infection did not occur, despite severe manifestations in the mothers.
Keywords: Antibody transfer; Case report; Pregnancy; Tick-borne encephalitis; Transmission.
Copyright © 2020 Elsevier GmbH. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest Dr. Dobler reports honoraria for lectures and fees for consulting by Pfizer Vaccines unrelated to the submitted work. Dr. Louwen reports personal fees from Nestlé and Milupa and non-financial support from the German Ministry of Health unrelated to the submitted work. Dr. Strzelczyk reports grants and/or personal fees from Desitin Arzneimittel, Eisai, GW pharmaceuticals, LivaNova, Marinus pharmaceuticals, Medtronic, Sage therapeutics, UCB pharma, Zogenix and Arvelle Therapeutics unrelated to the submitted work.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
